• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Markets
  3. / Regulation

Ackman Again Whipsawed by Herbalife, Valeant as Regulators Disappoint Pershing

It looks like the billionaire activist can't catch a break on these two stocks.
By JAMES PASSERI Jul 15, 2016 | 11:29 AM EDT
Stocks quotes in this article: HLF, VRX, VSI

Bill Ackman's Pershing Square hedge fund just can't seem to catch a break with regulators.

On one hand, Herbalife  (HLF)  -- the company Pershing shorted for about $1 billion in December 2012 -- skyrocketed as much as 18% in early trading Friday, on news that the FTC has finally concluded the nutrition-products distributor is not what Ackman has alleged: namely, an illicit pyramid scheme.

And on the other, Valeant Pharmaceuticals  (VRX) -- Pershing's biggest long flop to date -- dipped about 2% in morning trading as one of a trio of key drugs under Food and Drug Administration review appears to be encountering newfound hurdles.

The Federal Trade Commission's investigation into Herbalife began in earnest in March 2014, after Pershing's own probes into the company prompted a thorough look at Herbalife's compensation structure for vendors, who Ackman alleges very rarely turn a profit, are encouraged to rope new members into the so-called "scheme" rather than selling nutrition products, and are often run into debt after being pushed to start Herbalife franchises under the promises of million-dollar payouts.

But shares have since climbed 153% since their December 2012 trough, partially because of Ackman's feud with rival activist Carl Icahn, whose Icahn Associates unveiled a bullish bet in Herbalife that quickly accumulated into 13% of Herbalife's market cap just two months after Ackman's 2012 short was announced.

And as part of his longstanding battle with Herbalife -- in which Herbalife has sometimes fired back, calling Ackman a "Wall Street gambler" who made a "reckless bet" -- Ackman has long encouraged investors not to underestimate the gravity of the FTC probe.

Investors "appear to ignore the fact that the company may not be able to settle with the FTC, and instead, will be sued by the FTC for being a pyramid scheme," Ackman said in a May letter to Pershing shareholders.

Ackman most recently unveiled the 18th video of a Pershing-sponsored Web series focusing what he calls Herbalife's "victims." The videos are often cast against black backdrops with ominous music, as former Herbalife vendors recount financial and social collapses that they attribute to misinformation and pressure levied by Herbalife. On Thursday's CNBC "Halftime Report," Ackman also said in a phone interview that Herbalife shares remain substantially undervalued.

The findings of the FTC probe, rolled out Friday, are that Herbalife will have to pay a $200 million fine (which Herbalife has anticipated), a $3 million settlement with the Illinois Attorney General, and requests to reorder segments of its business model.

Herbalife also announced Friday that its agreement with Carl Icahn now allows him to raise his investment in the company by 15 million shares to his current position of 17 million.

"I have always believed in Herbalife's strong fundamentals and am pleased the Board has decided to increase my ownership limit from 25% to 34.99% of the Company's outstanding shares. A significant part of my investment success is directly tied to our in-depth investment research and understanding of often complex and unique issues facing companies," Icahn said in a statement.

And taking away all the "short-sell fireworks," Herbalife should trade more on an earnings-adjusted level with Vitamin Shoppe (VSI) , now that it is free of the pyramid-scheme image, Real Money's Jim Cramer said in a Friday report.

"My take: You pay up to $66 and then after that you are just speculating on Ackman vs. Icahn and how much they hate each other, and I think the answer is not enough to rely on anything but the earnings to get you past this analysis," Cramer added.

As for Valeant, all eyes have been on how the debt-laden drugmaker can shore up new cash to cope with a roughly $31 billion debt stack and Friday's announcement that a key pipeline drug, psoriasis treatment Brodalumab, appears to be struggling to obtain FDA approval. That decision is slated for later this month. The drug may pose a risk for suicidal thoughts among users, the FDA said in a Friday report.

Brodalumab was projected to contribute about $500 million in added sales to Valeant, and at hefty margins, due to its easy integration with Valeant's dermatology businesses, Rodman & Renshaw managing director Raghuram Selvaraju said in a Thursday interview with Real Money.

But Valeant still has two other pipeline drugs slated for approval this month, each of which could pull in about $500 million in new annual sales as soon as the fourth quarter, Selvaraju said. One, glaucoma treatment Latanoprostene bunod, could easily integrate into Valeant's Bausch & Lomb businesses, and fellow pipeline drug Relistor Oral would fit well with Valeant's Salix brand, which it acquired last April for $11 billion, he added.

Both of the remaining drugs will "almost certainly" be approved this month, said TD Securities analyst Lennox Gibbs in a Thursday report.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Regulation | Markets | Consumer | Short-selling | Stocks

More from Regulation

Investors to Suffer as Company Director Details Obscured in Hong Kong

Alex Frew McMillan
Mar 31, 2021 9:00 AM EDT

The Hong Kong government wants to change public-record rules in a way that encourages fraud and abuse.

Time to Take Some Bitcoin Chips Off the Table

Peter Tchir
Feb 17, 2021 10:00 AM EST

Here's what has me nervous now.

How to Stop Skyrocketing Share Prices? Let's Count the Ways

Timothy Collins
Jan 28, 2021 1:27 PM EST

I fully expect some new regulation to come down from the market action of the past two weeks.

Bright Cannabis Outlook Leads to Bigger Estimates for 2022

Debra Borchardt
Jan 25, 2021 5:15 PM EST

The fundamentals of the cannabis industry continue to improve.

As New Biden Regulations Move Forward, There's Fallout in Some Sectors

James "Rev Shark" DePorre
Jan 21, 2021 10:36 AM EST

This looks like consolidation after a big run rather than a major shift in market character.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login